Zonisamide and psychosis

https://doi.org/10.1016/S0896-6974(96)00083-7Get rights and content

First page preview

First page preview
Click to open first page preview

References (18)

  • SuzukiS et al.

    Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex

    Epilepsy Res

    (1992)
  • OkadaM et al.

    Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ dependent dopamine release

    Epilepsy Res

    (1992)
  • MasudaY et al.

    3-Sulfamoyl-methyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile

    Arzneimittelforschung

    (1980)
  • SeinoM et al.

    Zonisamide

  • YagiK et al.

    Methodological requirements for clinical trials in refractory epilepsies—our experience with zonisamide

    Prog Neuropsychopharmacol Biol Psychiatry

    (1992)
  • OnoT et al.

    Clinical efficacy and safety of new antiepileptics: zonisamide (in Japanese)

    Seishin-Igaku

    (1988)
  • MayaharaK et al.

    Zonisamide and epileptic psychosis, (in Japanese with English abstract)

    J Jpn Epil Soc

    (1995)
  • KawasakiJ et al.

    The occurrence of acute paranoid-hallucinatory state in epilepsy—in association with antiepileptic drugs (in Japanese)

    Seishin-Igaku

    (1991)
  • MatsuuraM et al.

    Eight epileptic patients showing delusional-hallucinatory state during zonisamide administration (in Japanese)

    Seishin-Igaku

    (1993)
There are more references available in the full text version of this article.

Cited by (28)

  • Epilepsy and psychosis

    2024, Revue Neurologique
  • Increased frequency of psychosis after second-generation antiepileptic drug administration in adults with focal epilepsy

    2019, Epilepsy and Behavior
    Citation Excerpt :

    While the frequency varies with each SAED (2.7–3.4%), each frequency is considerably higher. Reports on SAED-related psychoses have recently increased; e.g., vigabatrin (VGB) [26,27], ZNS [28], tiagabine (TGB) [29], LTG [30,31], TPM, [32,33], LEV [34,35], and GBP [36]. Whereas large controlled studies are limited, several comprehensive studies have reported a higher frequency of PAP with some SAED; ZNS [8,37], LEV [8], VGB [8], and TGB [8,10].

  • Pharmacotherapy in patients with epilepsy and psychosis

    2018, Epilepsy and Behavior
    Citation Excerpt :

    Some authors have strongly advocated that any potent AED can precipitate psychosis precisely because of the potent antiepileptic effects and that a subgroup of patients is particularly vulnerable to dramatic seizure reduction, irrespective of the AED used. In contrast, there are reports of psychotic symptoms specifically after exposure to certain AEDs [30–33] (including; ethosuximide [34], topiramate [35], felbamate [36], levetiracetam [37], zonisamide [38], vigabatrin [39], tiagabine [40], and lacosamide [41]). Whether they are specifically causal in the development of psychosis or not remains open to debate for reasons stated above.

  • Impact of antiepileptic drugs on genesis of psychosis

    2012, Epilepsy and Behavior
    Citation Excerpt :

    A line of case studies [23–27] has reported occurrence of frank psychosis in patients who received ZNS. Matsuura and Trimble [27] reported that the incidence of psychosis in patients treated with ZNS ranged from 1.9% to 2.3%, while the study of Miyamoto et al. [28] of 74 patients found that the incidence was much greater, ranging from 13% to 18%. According to the studies of White et al. [29] and Weintraub et al. [30], who used logistic regression analysis, ZNS possibly triggers various psychiatric symptoms, including depression, anxiety, and irritability, as well as psychosis.

View all citing articles on Scopus
View full text